Transperineal prostate biopsies without routine administration of perioperative antibiotics: A single-institution retrospective analysis.

Authors

null

Benjamin Lichtbroun

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Benjamin Lichtbroun , Mann Patel , Labeeqa Khizir , Munisa Said , Alexis Consalvo , Austin Chien , Kevin J. Chua , Arnav Srivastava , John Pfail , Sammy Elsamra , Thomas L. Jang , Saum Ghodoussipour

Organizations

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, University of Pennsylvania Health System, Philadelphia, PA, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Research Funding

No funding sources reported

Background: Infections are the most feared complication of transrectal prostate biopsy. Unfortunately, these complications are not infrequent. With antibiotic resistance becoming increasingly common, our institution has transitioned to a transperineal approach without use of perioperative antibiotics or bowel preparation. Given this significant change in practice pattern, we retrospectively analyzed these patients for rates of post-operative complications, 30-day hospital readmissions, and detection of prostate cancer. Methods: We retrospectively analyzed 146 patients who underwent a transperineal prostate biopsy at our institution in 2022. We recorded rates of complications including UTIs, sepsis, hematuria, and 30-day hospital readmissions. We also analyzed the percentage of patients found to have prostate cancer. Results: Of the 146 patients analyzed, 8 patients received peri-operative antibiotics (5.47%) - this was at the discretion of the surgeon performing the procedure. The reason 8 patients received peri-operative antibiotics was due to a prior infectious complication following a previous transrectal prostate biopsy. No patient received bowel preparation. Pre-procedure MRI was performed in 134 patients who had a MRI-ultrasound fusion biopsy. Hematuria was reported in 12 patients (8.21%) and there were zero infectious complications (UTI or sepsis). There were no 30-day readmissions amongst this cohort. Median procedure time was 24 minutes (Table). 86 patients were found to have adenocarcinoma (58.90) while 48 patients had benign pathology (32.87%). Conclusions: Despite a small percentage of patients receiving perioperative antibiotics, we had zero patients develop sepsis or an UTI. Our 30-day readmission rate was also 0%. With the high reported rates of infectious complications after transrectal prostate biopsy and antibiotic resistance becoming increasingly common, our data supports the notion that transperineal prostate biopsies are safe and can largely be done without the use of perioperative antibiotics.

Pre-biopsy and biopsy characteristics.
Median (IQR) or n (%)
Procedure time (minutes)24 (20-30)
Pre-operative antibiotics used8 (5.47)
Median number of biopsy cores15 (15-15)
Postprocedural complications
None129 (88.35)
Hematuria12 (8.21)
Sepsis0 (0)
Urinary tract infection0 (0)
30 day hospital readmission0 (0)
Other6 (4.10)

Continuous variables presented as median +IQR. Categorical variables presented as count (percent of total group).

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 310)

DOI

10.1200/JCO.2024.42.4_suppl.310

Abstract #

310

Poster Bd #

N1

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Genitourinary Cancers Symposium

Randomized trial of transperineal versus transrectal prostate biopsy to prevent infection complications.

First Author: Jim C. Hu

Abstract

2024 ASCO Genitourinary Cancers Symposium

Hierarchical clustering analysis for predicting 30-day readmissions after major surgery for prostate cancer.

First Author: Atulya Aman Khosla

First Author: Joshua Mabellos

First Author: Christopher J.D. Wallis